# Clinical Trials Data KRAS - Document 6

# NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT00856375

"eligibilityCriteria": "Inclusion Criteria:\n\n\* metastatic colorectal cancer\n\* tumor with k-ras mutation\n\nExclusion Criteria:\n\n\* More than 1 prior regimen for treatment of metastatic disease",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with a KRAS gene mutation and metastatic colorectal cancer \*would be potentially eligible\* for this trial based on the inclusion criteria listed. However, they would be excluded if they've already received more than one prior regimen for treatment of metastatic disease. Also, they must be 18 years or older.